Login
Companies $NPCE
$7.85 -$0.12 (1.51%) After hours
NeuroPace Inc logo

NeuroPace Inc

neuropace.com

What Do They Do?

Sells an implanted system that monitors brain activity and delivers targeted stimulation to treat adults with drug-resistant focal epilepsy, primarily through hospitals and comprehensive epilepsy centers.

How Do They Make Money?

Hospitals buy RNS systems and related products, with sales occurring when the device is implanted or, for advance orders, delivered; hospitals also pay for clinician access to the data platforms over the access period. Rapport pays for biomarker monitoring over its support period and for data analysis when the work is completed.

FY2025 revenue

Who Are Their Customers?

Hospitals, typically comprehensive epilepsy centers, buy RNS systems; the company’s sales team works directly with prescribing epileptologists and implanting neurosurgeons. Rapport Therapeutics also buys biomarker-monitoring and data-analysis services.

Do Revenues Turn Into Profits?

No. It lost $21.5M in FY2025.

Operating income, FY2025
−16% of revenue
▲ +25% (Loss) vs FY2024 (−$21.7M, −27%)
Net income, FY2025
−21% of revenue
▲ +21% (Loss) vs FY2024 (−$27.1M, −34%)
Free cash flow, FY2025
−11% of revenue
▲ +38% (Loss) vs FY2024 (−$18.3M, −23%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −1%
vs $23.4M in Q3 FY2025
Net income
▲ +6% (Loss)
vs −$3.5M in Q3 FY2025
  • Nov 12, 2026 Revises full-year revenue guidance The revised full-year 2026 revenue guidance is $91 million to $92 million.

Growing. Revenue grew 2.2x in 4 years, from $45.2M in FY2021 to $100M in FY2025, about 22% a year.

Broader clinician reach The older report describes sales focused on comprehensive epilepsy centers. The latest report adds outreach to epileptologists outside those centers and functional neurosurgeons, widening the clinician base the sales team targets.

Who Do They Compete With?

Competes with LivaNova and Medtronic

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support